Relationship between response to lusutrombopag and splenic volume

作     者：Haruki Uojima Yoshitaka Arase Norio Itokawa Masanori Atsukawa Takashi Satoh Koji Miyazaki Hisashi Hidaka Ji Hyun Sung Makoto Kako Kota Tsuruya Tatehiro Kagawa Katsuhiko Iwakiri Ryouichi Horie Wasaburo Koizumi 

作者机构：Department of GastroenterologyShonan Kamakura General Hospital Department of GastroenterologyInternal MedicineKitasato University School of Medicine Division of Gastroenterology and HepatologyDepartment of Internal MedicineTokai University School of Medicine Department of Internal MedicineDivision of GastroenterologyNippon Medical School Chiba Hokusoh Hospital Department of Internal MedicineDivision of Gastroenterology and HepatologyNippon Medical School Division of HematologyDepartment of Medical Laboratory SciencesKitasato University School of Allied Health Sciences Division of Molecular HematologyKitasato University Graduate School of Medical Sciences Department of Transfusion and Cell TransplantationKitasato University School of Medicine 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2018年第24卷第46期

页      面：5271-5279页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

基　　金：Japan Society for the Promotion of Science  JSPS  (17K08728) 

主　　题：Lusutrombopag Portal hypertension Splenic volume Thrombocytopenia Thrombopoietin receptor agonist 

摘      要：AIM To assess the correlation between the efficacy of lusutrom-bopag and clinical characteristics in patients with chronic liver *** In this retrospective, multicenter study, which conducted at four locations in Japan, 50 thrombocytopenic patients with chronic liver disease were enrolled. All patients received oral lusutrombopag(3.0 mg/d for 7 d) for chronic liver disease. We assessed the increase in platelet count after the trial drug administration. A treatment response was defined as a platelet count ≥ 5 × 104/μL and an increased platelet count ≥ 2 × 104/μL from baseline after drug administration. We evaluated the response to lusutrombopag compared to baseline clinical characteristics in patients with chronic liver *** The numbers of responders and non-responders were 40(80.0%) and 10(20.0%), respectively. The patients were divided into a responder and non-responder group, and we added factors that may correspond to successful treatment with lusutrombopag. Splenic volume and body weight were lower in the responder group than in the nonresponder group. White blood cell count and hemoglobin level were higher in responders compared with nonresponders. Using a logistic regression model to assess the relationship between response to lusutrombopag and clinical characteristics, multivariate analysis confirmed that splenic volume was an independent factor that predicted the response of platelet counts(P = 0.025; odds ratio = 11.2; 95% confidence interval: 1.354-103.0). Splenic volume negatively correlated to changes in platelet count(r =-0.524, P = 0.001).CONCLUSION Splenic volume influences the change in platelet counts after administration of lusutrombopag in patients with chronic liver disease.